NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
Clinical Trials
39 trialsNCT07455019 2026-03-06
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07398326 2026-02-09
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT06662006 2026-02-06
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small MoleculeĀ±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT07363512 2026-01-23
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06767813 2025-09-19
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT07142421 2025-08-26
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT07128693 2025-08-19
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT07025174 2025-06-17
SAIB
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06901622 2025-03-30
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Enrolling by invitation
NCT06621095 2024-10-01
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
RenJi Hospital
Phase 2 Not yet recruiting
NCT04278222 2024-07-10
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT05229003 2024-07-03
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
Phase 2 Recruiting
NCT06426797 2024-05-23
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT05493995 2024-05-09
PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT04271813 2024-04-23
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
Shanghai Changzheng Hospital
Phase 2 Completed
NCT05029102 2024-02-12
TAS-102 and Anlotinib in ā„3 Lines mGC
Zhejiang University
Phase 2 Unknown
NCT06222944 2024-01-25
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Peking University
Phase 2 Not yet recruiting
NCT05262335 2023-11-28
ALTER-G-001
Ruijin Hospital
Phase 2 Unknown
NCT06051851 2023-09-25
RCT-PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT06031480 2023-09-11
FAITH
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT06015035 2023-08-29
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Tang-Du Hospital
Phase 2 Completed
NCT05996484 2023-08-21
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT05866510 2023-05-19
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
Peking University
Phase 2 Unknown
NCT05322499 2022-04-11
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04970914 2022-03-08
ALTER-C003
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03387904 2021-09-02
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04947371 2021-07-01
Adjuvant Therapy With Anlotinib for HCC
Shanghai Zhongshan Hospital
Phase 2 Withdrawn
NCT04797507 2021-03-15
SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04777162 2021-03-04
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
Phase 2 Unknown
NCT04207463 2020-06-17
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04080154 2020-04-03
ALTER-H-002
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04300959 2020-03-09
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04157140 2019-12-03
Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
Beijing Ditan Hospital
Phase 2 Unknown
NCT04106024 2019-09-26
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
Cttq
Phase 2 Unknown
NCT04066543 2019-08-26
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT02649361 2019-06-05
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT03457844 2018-09-11
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT02809534 2016-09-07
ALTER0802
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown